To evaluate efficacy and safety profile of DC bead® TACE in patients with hepatocellular carcinoma in Taiwan.

To evaluate efficacy and safety profile of DC bead TACE in patients with hepatocellular carcinoma in Taiwan.

This is a multi-center, retrospective, single arm study to explore safety and efficacy of DC bead TACE in hepatocellular carcinoma (HCC) in Taiwan

Retrospective analysis of medical records of all patients who underwent DC Bead TACE at National Taiwan University Hospital, National Cheng Kung University Hospital, and Taichung Veterans General Hospital from 2010-2017/7.

All statistical data were analyzed with SPSS software (SPSS, IBM North America, New York, NY, USA). Demographic and baseline lab data are presented by using descriptive statistics Student's t-test. Survival analysis will includes all patients.

Inclusion Criteria:

• Patients with a diagnosis of HCC, according to the AASLD diagnosis criteria for HCC.
• Patient received DC bead TACE.

Exclusion Criteria:

• Patients with current any other cancer except non-melanomatous skin cancer.
• Infiltrative HCC
• Patients received ≥2 consecutive sessions of TACE (≥2 TACE at the same admission, no matter it is cTACE or DC bead TACE)
• Patients received DC bead TACE and simultaneously received other therapy, such as radiotherapy, sorafenib etc.
• Presence of collateral vessel pathways potentially endangering normal territories during embolization.
• Presence of arteries supplying the lesion not large enough to accept DC Bead® microspheres.

Medical records of all patients who underwent DC bead TACE at National Taiwan University Hospital, National Cheng Kung University Hospital, and Taichung Veterans General Hospital from 2010-2017/7